Joseph Choo, MD
Interventional Cardiology · Cincinnati, OHNPI 1760468797
Payments from drug & device makers
Across 660 payments — averaging $2923.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$808K
- Boston Scientific$673K
- Abbott$236K
- Medtronic$118K
- Johnson & Johnson$72K
- AstraZeneca$13K
- plus $8K from 28 others
What the payments were for
- Consulting fees$71,42532%
- Speaking & faculty fees$88,55540%
- Travel & lodging$44,67720%
- Food & beverage$18,8638%
- Education$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 133 | $808,278 |
| Boston Scientific | 99 | $673,098 |
| Abbott | 141 | $235,840 |
| Medtronic(2 entities) | 138 | $118,192 |
| Johnson & Johnson | 60 | $72,381 |
| AstraZeneca | 16 | $13,143 |
| Esperion Therapeutics, Inc. | 1 | $1,980 |
| Ancora Heart, Inc. | 9 | $1,940 |
| W. L. Gore & Associates, Inc. | 6 | $983 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $463 |
| Shockwave Medical, Inc | 5 | $414 |
| Recor Medical Inc | 4 | $388 |
| Endotronix, Inc. | 1 | $299 |
| United Therapeutics Corporation | 2 | $250 |
| Biotronik Inc. | 11 | $195 |
| Teleflex LLC | 2 | $186 |
| Heartflow, Inc. | 2 | $151 |
| Asahi Intecc USA, Inc. | 1 | $145 |
| Cvrx, Inc. | 1 | $129 |
| Bridgebio Pharma, Inc. | 1 | $125 |
| Philips North America LLC | 2 | $91 |
| Penumbra, Inc. | 1 | $91 |
| Biosense Webster, Inc. | 1 | $90 |
| Regeneron Healthcare Solutions, Inc. | 4 | $65 |
| Reflow Medical Inc | 2 | $65 |
| Impulse Dynamics (USA) Inc. | 2 | $50 |
| Novartis | 2 | $42 |
| Chiesi USA, Inc. | 2 | $26 |
| Genentech USA, Inc. | 1 | $19 |
| Boehringer Ingelheim | 1 | $15 |
| Angiodynamics, Inc. | 1 | $14 |
| Pfizer | 1 | $12 |
| E.r. Squibb & Sons, L.L.C. | 1 | $11 |
| Bardy Diagnostics, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$71,436
- Mitra Clip system$48,028
- MitraClip$30,449
- FARXIGA$13,115
- Edwards SAPIEN 3 Transcatheter Heart Valve$8,083
- GENERAL - THERAPIES$7,424
- MitraClip System$7,332
- TRICLIP$4,530
- NEXLIZET$1,980
- NEXLETOL$1,980
- CoreValve Evolut$1,917
- AccuCinch$1,764
- EVOQUE$1,652
- GENERAL - STRUCTURAL HEART$1,000
- SAPIEN 3 Ultra RESILIA$682
- COREVALVE EVOLUT R$649
- Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$299
- CORDELLA PULOMONARY ARTERY PRESSURE SENSOR$299
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$252
- WATCHMAN Access System$249
How this compares
$1,929,180 in reported general payments places this provider in the 95th percentile of 256 interventional cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 272 | $278,331 |
| XareltoRivaroxaban | 85 | $90,838 |
| EntrestoSacubitril/Valsartan | 72 | $74,202 |
| Repatha SureclickEvolocumab | 32 | $24,610 |
| Repatha PushtronexEvolocumab | 12 | $10,452 |
| JardianceEmpagliflozin | 12 | $7,114 |
| Ranolazine ErRanolazine | 44 | $4,576 |
| Ezetimibe | 161 | $2,593 |
| Rosuvastatin Calcium | 141 | $2,300 |
| Atorvastatin Calcium | 299 | $2,137 |
| Eplerenone | 13 | $1,350 |
| Metoprolol Succinate | 131 | $1,195 |
| ClopidogrelClopidogrel Bisulfate | 109 | $1,127 |
| Amlodipine Besylate | 165 | $1,050 |
| Spironolactone | 198 | $1,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $12 | $278,331272 claims |
| Johnson & JohnsonXarelto | $72,381 | $90,83885 claims |
| NovartisEntresto | $42 | $74,20272 claims |
| Boehringer IngelheimJardiance | $15 | $7,11412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 256 interventional cardiology providers in Ohio.
Other interventional cardiology in Cincinnati
- Santiago GarciaCincinnati$3.6M
- Dean KereiakesCincinnati$3.4M
- Timothy HenryCincinnati$1.3M
- John CorlCincinnati$793K
- Ian SarembockCincinnati$266K
- Puvi SeshiahCincinnati$230K
- Steven RudickCincinnati$216K
- Imran ArifCincinnati$127K
- Jonathan RappCincinnati$91K
- Raviteja GuddetiCincinnati$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.